Chapter 5 · Module 2 · Visual Summary
Epinephrine · Norepinephrine · Dopamine · Dobutamine
Drug Profiles at a Glance
Epinephrine
Full Alpha + Beta Agonist
Norepinephrine
Predominant Alpha + Beta-1
Dopamine
Dose-Dependent Receptor Profile
Dobutamine
Selective Beta-1 Inotrope
High-Risk Drug Interactions
| Interacting Drug | Risk Level | Mechanism and Effect | Management |
|---|---|---|---|
| Monoamine oxidase inhibitors | DANGEROUS | Irreversible enzyme inhibition → catecholamine accumulation → hypertensive crisis. Effect persists 2 weeks after stopping. | Avoid catecholamines for 2 weeks. Use phenylephrine if vasopressor required. |
| Tricyclic antidepressants | CAUTION | Norepinephrine transporter blockade → prolonged catecholamine effect. Indirect agents less effective. | Reduce direct catecholamine doses; monitor closely. |
| Non-selective beta-blockers (anaphylaxis) | DANGEROUS | Beta-2 blockade → unopposed alpha-1 → paradoxical hypertension + persistent bronchospasm despite epinephrine. | Glucagon 1–2 mg intravenous (bypasses blocked receptors via Gs). Add ipratropium. |
| Cocaine intoxication | DANGEROUS | Norepinephrine transporter blockade → catecholamine excess. Additional sympathomimetics risk crisis. Beta-blockers contraindicated (unopposed alpha-1). | Benzodiazepines; phentolamine for hypertension; nitrates. No beta-blockers. |